Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC (ETNT)
Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After Neoadjuvant Chemoradiotherapy in Resected Locally Advanced Esophageal Squamous Cell Carcinoma: an Exploratory Study
Sponsor: Sichuan Cancer Hospital and Research Institute
This PHASE2 trial investigates Esophageal Squamous Cell Carcinoma and is currently ongoing. Sichuan Cancer Hospital and Research Institute leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting PHASE2
Status: Unknown → Active Not Recruiting
-
Sep 2024 — Dec 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Mar 2024 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Mar 2022 — Mar 2024 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE2
First recorded
Jul 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sichuan Cancer Hospital and Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .